VEGFA and fibrosis: Fibrosis is more likely to occur in type 2 macular neovascularization, larger lesions at treatment initiation and in the presence of high-risk features such as subretinal blood and hyperreflective material (HRM) on spectral domain OCT (SD-OCT) at presentation.10, 11, 12, 13, 14, 15 In 1 study with long-term follow-up, nearly half of eyes without fibrosis at baseline undergoing ongoing anti-VEGF treatment developed fibrosis by 8.3 years.16